• 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • Resiniferatoxin Table shows the average absorbed dose per nu


    Table 2 shows the average absorbed dose per nuclear transforma-
    blem of recoil energy of the nucleus during decay, which can provoke
    progeny, as well as for 177Lu. As can be observed in Table 3, 225Ac- the breaking of the bond with the molecule chelator, allowing the re-
    iPSMA releases a nine hundred-fold greater radiation dose than 177Lu- lease of the daughter radionuclide from the chelate. However, as in the
    iPSMA and 14 times more than 223 RaCl2 per unit of activity retained in case of radio-lanthanides used as bone-seeking agents (e.g. 153Sm+3
    and 177 Lu +3 ), it is highly probable that free radionuclides remain as
    bone. Although high dose values are observed per Bq in the bone model
    immobile compounds in the osseous tissue and also position themselves
    of 223RaCl2 or 225Ac-iPSMA to patients is around 7 MBq (Nilsson et al., extremely close to cancer cells. (Volkert and Hoffman, 1999; Yoshida
    2007; Kratochwil et al., 2018); therefore, the maximum activity ex- et al., 2016). Nevertheless, experimental models are necessary to
    evaluate the RBE value of 225Ac-iPSMA and the biodistribution of free
    225Ac daughter radionuclides in bone as a consequence of the recoil
    bone) is in the order of μBq. In the case of 177Lu-iPSMA, the adminis-
    iPSMA, which signifies that in clinical applications both radio- 4. Conclusions
    pharmaceuticals are delivering the same radiation absorbed dose to 225Ac-iPSMA has potential dosimetric and radiobiological ad-
    cancer Resiniferatoxin in patients. However, in this issue the RBE effect is relevant
    since, as the linear energy transfer (LET) increases, radiation produces vantages over 177Lu-iPSMA and 223RaCl2 in the treatment of bone
    E. Azorín-Vega et al.
    metastases in patients with advanced prostate cancer. Experimental models are necessary to evaluate the relative biological effectiveness value of 225Ac-iPSMA as well as its stability in bone tissue.
    Conflicts of interest
    The authors declare no competing financial interest.
    This study was performed as part of the activities of the “Laboratorio Nacional de Investigación y Desarrollo de Radiofármacos-CONACyT”. Grant 293334.
    Appendix A. Supplementary data
    metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 19 (6), 825–833.
    International Comission on Radiation Units and Measurements, 1989. Tissue Substitutes in Radiation Dosimetry and Measurement, vol. 23 1. os23.1.Report44. International Commission on Radiation Protection, 1995. Basic anatomical & physiolo-gical data for use in radiological protection - the Strand displacement skeleton. ICRP publication 70. Ann. ICRP 25 (2). Kratochwil, C., Bruchertseifer, F., Rathke, H., Hohenfellner, M., Giesel, F.L., Haberkorn, U., Morgenstern, A., 2018. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy re-garding duration of tumor control. J. Nucl. Med. 59 (5), 795–802.
    Luna-Gutierrez, M., Hernandez-Jimenez, T., Serrano-Espinoza, L., Pena-Flores, A., Soto-Abundiz, A., 2017. Freeze-dried multi-dose kits for the fast preparation of 177Lu-Tyr3-octreotide and 177Lu-PSMA(inhibitor) under GMP conditions. J. Radioanal. Nucl.
    Wüstemann, T., Bauder-Wüst, U., Schäfer, M., Eder, M., Benesova, M., Leotta, K., 2016. Design of internalizing PSMA-specific Glu-ureido-based radiotherapeuticals.
    Contents lists available at ScienceDirect
    Lung Cancer
    journal homepage:
    Association between antibiotic-immunotherapy exposure ratio and outcome T in metastatic non small cell lung cancer
    Giulia Gallia, Tiziana Triulzib, Claudia Protoa, Diego Signorellia, Martina Imbimboa, Marta Poggia, Giovanni Fucàa, Monica Ganzinellia, Milena Vitalia, Dario Palmierid, Anna Tessarid,
    Filippo de Brauda,c, Marina Chiara Garassinoa, Mario Paolo Colombob, Giuseppe Lo Russoa,
    a Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian 1, 20133, Milan, Italy
    b Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, via Amadeo 42, 20133, Milan, Italy
    c Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, via Festa del Perdono 7, 20122, Milan, Italy
    d Department of Cancer Biology and Genetics, The Ohio State University, 460w 12th avenue, 43210, Columbus, OH, USA
    Non small cell lung cancer